Real‐world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program. (15th April 2020)
- Record Type:
- Journal Article
- Title:
- Real‐world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program. (15th April 2020)
- Main Title:
- Real‐world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program
- Authors:
- Wharton, Sean
Haase, Christiane L
Kamran, Elham
Liu, Aiden
Mancini, Johanna
Neish, Drew
Pakseresht, Arash
Power, G Sarah
Christensen, Rebecca AG - Abstract:
- Summary: Objective: Weight management medications can significantly increase patients' chances of achieving a clinically meaningful weight loss if patients persist with treatment. This retrospective observational study of de‐identified medical records of 311 patients is the first real‐world study examining persistence with liraglutide 3.0 mg in Canada, and also investigates associations between the SaxendaCare® patient support program and persistence and weight loss. Methods: Overall persistence was assessed, as well as associations of enrollment in SaxendaCare®, persistence and weight loss. Results: Overall mean (standard deviation) persistence with liraglutide 3.0 mg was 6.3 (4.1) months, and 67.5% ( n = 210) and 53.7% ( n = 167) of patients persisted for ≥4 and ≥ 6 months, respectively. Enrollment in SaxendaCare® was associated with significantly longer persistence with liraglutide 3.0 mg and greater weight loss. Patients enrolled in SaxendaCare® ( n = 119) persisted for 7.9 (4.0) versus 5.2 (3.8) months for those not enrolled ( n = 184) ( p < 0.001), and had significantly greater percent weight loss after 6 months regardless of the duration of their persistence (−7.9% vs −5.5% from baseline, p < 0.01). Conclusions: These findings suggest that, in clinical settings, persistence with liraglutide 3.0 mg can exceed 6 months, and that enrolling in SaxendaCare® may be associated with comparatively longer persistence and, regardless of persistence, greater weight loss.
- Is Part Of:
- Obesity science and practice. Volume 6:Number 4(2020)
- Journal:
- Obesity science and practice
- Issue:
- Volume 6:Number 4(2020)
- Issue Display:
- Volume 6, Issue 4 (2020)
- Year:
- 2020
- Volume:
- 6
- Issue:
- 4
- Issue Sort Value:
- 2020-0006-0004-0000
- Page Start:
- 382
- Page End:
- 389
- Publication Date:
- 2020-04-15
- Subjects:
- Liraglutide 3.0 mg -- obesity -- persistence -- SaxendaCare®
Obesity -- Periodicals
616.398005 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2055-2238 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/osp4.419 ↗
- Languages:
- English
- ISSNs:
- 2055-2238
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 13911.xml